Chapter 11  ·  Module 2

Statins: Mechanisms and Pharmacology

Visual summary — mechanism of action, pharmacokinetics, intensity, and pleiotropic effects

Mechanism of Action — From Enzyme Inhibition to LDL Clearance

Step 1

Statin blocks HMG-CoA reductase

Rate-limiting step in mevalonate pathway blocked

→

Step 2

Hepatic cholesterol synthesis falls

Intracellular cholesterol depleted

→

Step 3

SREBP-2 pathway activates

Transcription factor released; LDL receptor gene upregulated

→

Result

More LDL receptors on hepatocyte surface

Increased LDL clearance from plasma

The Rule of 6s — Why Dose Doubling Has Diminishing Returns

SREBP-2 also upregulates PCSK9, which destroys LDL receptors. This counterregulatory brake means each statin dose doubling adds only ~6% more LDL reduction. Adding ezetimibe or a PCSK9 inhibitor is more effective than escalating beyond the statin dose ceiling.

Pharmacokinetic Classification — Metabolism and Interaction Risk

Statin Type Metabolism Interaction Risk Best Use
Atorvastatin Lipophilic CYP3A4 Moderate First choice; most versatile
Rosuvastatin Hydrophilic Minimal CYP Low Most potent; preferred with CYP3A4 inhibitors
Simvastatin Lipophilic CYP3A4 prodrug High Largely replaced; 80 mg restricted
Pravastatin Hydrophilic Non-CYP Low Transplant patients on cyclosporine
Lovastatin Lipophilic CYP3A4 High Historical; avoid with CYP3A4 inhibitors

Statin Intensity Classification

High intensity

LDL reduction ≥50%

  • Atorvastatin 40–80 mg
  • Rosuvastatin 20–40 mg
  • Use in secondary prevention and very high-risk patients

Moderate intensity

LDL reduction 30–49%

  • Atorvastatin 10–20 mg
  • Rosuvastatin 5–10 mg
  • Simvastatin 20–40 mg
  • Pravastatin 40–80 mg

Low intensity

LDL reduction <30%

  • Simvastatin 10 mg
  • Pravastatin 10–20 mg
  • Reserved for intolerance to higher intensities

Pleiotropic Effects — Beyond LDL Cholesterol Lowering

Vascular endothelium

Anti-inflammatory and Endothelial Effects

  • Reduce high-sensitivity C-reactive protein and inflammatory cytokines
  • Increase endothelial nitric oxide synthase activity
  • Improve nitric oxide-dependent vasodilation
  • Begin within days of initiation

Arterial wall and coagulation

Plaque Stabilization and Antithrombotic Effects

  • Reduce lipid core volume; increase fibrous cap thickness
  • Decrease macrophage infiltration in plaques
  • Reduce platelet aggregability and thromboxane synthesis
  • Explain early benefit in acute coronary syndrome

Clinical Key Point

High-intensity statin should be started within 24 hours of acute coronary syndrome — regardless of baseline LDL cholesterol. Pleiotropic effects (anti-inflammatory, plaque-stabilizing, endothelial) begin within days. LDL lowering is the dominant long-term driver of benefit, but these early effects matter acutely.